To investigate whether FJX1 affects the immunotherapy effect in cancer patients, we downloaded the immunotherapy dataset from IMvigor210CoreBiologies and found that in the immunotherapy-tolerant group, the FJX1 expression was higher compared with immunotherapy-effective group (p<0.05) (Supplementary Figure S5A). This evidence concerns the gene FJX1 and cancer.